Skip mediastinal lymph node metastasis in non-small cell lung cancer. 1994

M Tateishi, and Y Fukuyama, and M Hamatake, and S Kohdono, and T Ishida, and K Sugimachi
Department of Surgery II, Faculty of Medicine, Kyushu University, Fukuoka, Japan.

We retrospectively investigated 186 non-small cell lung cancer cases with N2 disease in order to clarify the significance of skip metastasis. Of the 186 patients with N2 disease, negative N1 nodes recognized to be skip metastasis were seen in 62 patients (33%). The incidence of skip metastasis was not statistically different regarding histology, T status, or M status. The incidence of the skip metastatic site consisted of 35 cases (56%) at sites 1, 2 and 3, while 8 cases (13%) were found at sites 8 and 9. Among the patients with right lung cancer, the skip metastatic incidence for site 7 (subcarinal) was higher in patients with either middle lobe or lower lobe cancer than in those with upper lobe cancer (P < 0.05). The 5-year survival rates of all N2 patients in comparison to those with skip metastasis were 22% and 24%, respectively. When the sites of mediastinal lymph nodes were classified as superior, aortic, and inferior, the 5-year survival rates of the patients with superior skip metastasis, aortic metastasis, and inferior metastasis were 23%, 36%, and 15%, respectively. No statistical difference was observed. The 5-year survival rate of the skip N2 patients with only aortic region involvement was 50% (n = 7). However, no statistically significant difference was found between the two groups (P = 0.08). Our results thus suggested that mediastinal involvement for the aortic region alone might have a better prognosis than the others. We thus conclude that a dissection of the complete hilar and mediastinal lymph nodes should be the procedure of choice in standard operations for non-small cell lung cancer because of the high frequency of skip metastasis.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008297 Male Males
D008479 Mediastinal Neoplasms Tumors or cancer of the MEDIASTINUM. Cancer of Mediastinum,Mediastinal Cancer,Cancer of the Mediastinum,Mediastinum Cancer,Mediastinum Neoplasms,Neoplasms, Mediastinal,Cancer, Mediastinal,Cancer, Mediastinum,Cancers, Mediastinal,Cancers, Mediastinum,Mediastinal Cancers,Mediastinal Neoplasm,Mediastinum Cancers,Mediastinum Neoplasm,Neoplasm, Mediastinal,Neoplasm, Mediastinum,Neoplasms, Mediastinum
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

M Tateishi, and Y Fukuyama, and M Hamatake, and S Kohdono, and T Ishida, and K Sugimachi
October 1996, The Annals of thoracic surgery,
M Tateishi, and Y Fukuyama, and M Hamatake, and S Kohdono, and T Ishida, and K Sugimachi
May 2001, Zhonghua zhong liu za zhi [Chinese journal of oncology],
M Tateishi, and Y Fukuyama, and M Hamatake, and S Kohdono, and T Ishida, and K Sugimachi
April 2003, Journal of surgical oncology,
M Tateishi, and Y Fukuyama, and M Hamatake, and S Kohdono, and T Ishida, and K Sugimachi
December 2009, Lung cancer (Amsterdam, Netherlands),
M Tateishi, and Y Fukuyama, and M Hamatake, and S Kohdono, and T Ishida, and K Sugimachi
May 2019, Clinical lung cancer,
M Tateishi, and Y Fukuyama, and M Hamatake, and S Kohdono, and T Ishida, and K Sugimachi
August 2005, The Journal of thoracic and cardiovascular surgery,
M Tateishi, and Y Fukuyama, and M Hamatake, and S Kohdono, and T Ishida, and K Sugimachi
March 2018, Journal of thoracic disease,
M Tateishi, and Y Fukuyama, and M Hamatake, and S Kohdono, and T Ishida, and K Sugimachi
July 2005, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases,
M Tateishi, and Y Fukuyama, and M Hamatake, and S Kohdono, and T Ishida, and K Sugimachi
April 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer,
M Tateishi, and Y Fukuyama, and M Hamatake, and S Kohdono, and T Ishida, and K Sugimachi
January 2006, Zhonghua zhong liu za zhi [Chinese journal of oncology],
Copied contents to your clipboard!